



Sinclair IS Pharma plc

Amendment of Lock-up terms

Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair IS" or the "Company"), the international specialty pharma company, announces that in order to satisfy institutional demand, it has amended the terms of the lock-up arrangements with the ex-shareholders of Advanced Bio-Technologies Inc.

11,478,136 (57%) of the 19,990,000 ordinary shares issued as consideration have now been released four months post completion, as opposed to six months post completion as originally envisaged, with 10,000,000 of these being placed with investors. The remaining 45% remain subject to the same lock-up timetable with half of these being released on 15 December 2012 (the one year anniversary of the acquisition's completion) and the balance on 30 June 2013.

Ends

For further information please contact:

Sinclair IS Pharma plc

Chris Spooner
Alan Olby
Robert Taylor

Tel: +44 (0) 20 7467 6920

Jefferies Hoare Govett (NOMAD and Broker)

Nick Adams
Thomas Rider

Tel: +44 (0) 20 7029 8000

FTI Consulting

Ben Atwell
Stephanie Cuthbert

Tel: +44 (0) 20 7831 3113

Notes to Editors:

About Sinclair IS Pharma plc – www.sinclairispharma.com

Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed and emerging markets.